Non-medullary thyroid cancer (TCA), the most common type of endocrine malignancy, accounts for most deaths due to endocrine cancers. Although the majority of TCAs are successfully managed with surgery and radioactive iodine (I-131) ablative therapy, the mortality associated with this disease has remained stable over the years because these therapies are not effective for clinically aggressive tumors, which have accelerated patterns of growth and/or fail to trap iodine efficiently. This group consists of poorly-differentated and anaplastic TCAs, but also includes certain sub-groups of well-differentiated TCAs. The loss of iodine trapping ability by the malignant thyrocyte may be correlated with other cellular and molecular events that accompany de-differentiation. Our goal is to study the molecular events accompanying the natural history of clinically aggressive TCA and the response of various molecular markers to standard therapeutic intervention(s). Preoperative diagnostic methods include aspiration cytology, ultrasonography, thyroid scanning with I-131 and/or other radionuclides, and suppression therapy with L- thyroxine. Specific issues include: (i) optimization of methods of diagnostic scanning in TCA and serum thyroglobulin measurement to diagnose tumor recurrence, (ii) refinement of already established methods of administering I-131 therapy to improve the risk/benefit ratio, (iii) PCR-based detection and quantification of thyroid-specific mRNAs (e.g. thyroglobulin mRNA and mRNAs for other markers) in thyrocytes circulating in peripheral blood, (iv) analysis of mutations in genes involved in TCA growth, apoptosis, and mitotic cycle regulation, such as the thyrotropin receptor, ras, p53, Fas/Fas ligand, and ret/PTC in primary and metastatic thyroid tumors, and (v) establishment of immortalized cell lines from TCAs for in vitro studies. The relationship between the existence or absence of markers of differentiation and mutations in growth-relevant genes, and the clinical behavior of TCA will help define the pathways responsible for thyrocyte growth and differentiation, and guide the development of new therapeutic strategies to attack clinically aggressive TCAs by reverting them to a more benign differentiated phenotype.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Intramural Research (Z01)
Project #
1Z01DK055016-01
Application #
6105907
Study Section
Special Emphasis Panel (MCEB)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Sandrini, Fabiano; Matyakhina, Ludmila; Sarlis, Nicholas J et al. (2002) Regulatory subunit type I-alpha of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer. Genes Chromosomes Cancer 35:182-92
Yu, Juan; Steiner, Federico A; Muench, Jeffrey P et al. (2002) Juxtathyroidal neck soft tissue angiosarcoma presenting as an undifferentiated thyroid carcinoma. Thyroid 12:427-32
Hung, Wellington; Sarlis, Nicholas J (2002) Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 12:683-702
Koch, C A; Sarlis, N J (2001) The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management. J Endocrinol Invest 24:659-75
Uwaifo, G I; Remaley, A T; Stene, M et al. (2001) A case of spurious hypercalcitoninemia: a cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia. J Endocrinol Invest 24:361-9
Kitazono, M; Robey, R; Zhan, Z et al. (2001) Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86:3430-5
Smallridge, R C; Castro, M R; Morris, J C et al. (2001) Renal metastases from thyroid papillary carcinoma: study of sodium iodide symporter expression. Thyroid 11:795-804
Rotman-Pikielny, P; Reynolds, J C; Barker, W C et al. (2000) Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab 85:237-44
Csako, G; Byrd, D; Wesley, R A et al. (2000) Assessing the effects of thyroid suppression on benign solitary thyroid nodules. A model for using quantitative research synthesis. Medicine (Baltimore) 79:26-Sep
Sarlis, N J (2000) Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects. Rev Endocr Metab Disord 1:183-96